Voloridge Investment Management
LGND icon

Voloridge Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Voloridge Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,543
Closed -$2.5M – 960
2026
Q1 		$2.5M Buy
12,543
+505
+4% +$99.9K 0.01% 795
2025
Q4 		$2.28M Buy
12,038
+3,442
+40% +$661K 0.01% 899
2025
Q3 		$1.52M Buy
+8,596
New +$1.28M 0.01% 974
2023
Q4 		– Sell
-8,088
Closed -$485K – 1328
2023
Q3 		$485K Sell
8,088
-8,123
-50% -$535K ﹤0.01% 1215
2023
Q2 		$1.17M Sell
16,211
-8,045
-33% -$604K 0.01% 1093
2023
Q1 		$1.78M Buy
24,256
+11,628
+92% +$827K 0.01% 1004
2022
Q4 		$844K Buy
+12,628
New +$821K ﹤0.01% 1170
2021
Q4 		– Sell
-18,834
Closed -$1.64M – 1718
2021
Q3 		$1.64M Sell
18,834
-66,933
-78% -$5.18M 0.01% 1119
2021
Q2 		$7.02M Sell
85,767
-47,410
-36% -$3.94M 0.05% 521
2021
Q1 		$12.7M Buy
133,177
+94,888
+248% +$8.97M 0.09% 288
2020
Q4 		$2.38M Buy
38,289
+23,437
+158% +$1.34M 0.02% 670
2020
Q3 		$883K Sell
14,852
-18,976
-56% -$1.29M 0.01% 974
2020
Q2 		$2.36M Sell
33,828
-32,369
-49% -$2.05M 0.03% 566
2020
Q1 		$3M Buy
66,197
+30,992
+88% +$1.76M 0.09% 255
2019
Q4 		$2.29M Sell
35,205
-20,722
-37% -$1.38M 0.04% 457
2019
Q3 		$3.47M Buy
55,927
+11,873
+27% +$745K 0.06% 326
2019
Q2 		$3.14M Buy
44,054
+10,806
+33% +$796K 0.09% 247
2019
Q1 		$2.61M Sell
33,248
-31,879
-49% -$2.42M 0.08% 248
2018
Q4 		$5.51M Buy
+65,127
New +$6.94M 0.25% 108
2018
Q3 		– Sell
-62,604
Closed -$8.09M – 394
2018
Q2 		$8.09M Buy
62,604
+5,957
+11% +$665K 0.22% 110
2018
Q1 		$5.84M Buy
+56,647
New +$5.6M 0.14% 135
2017
Q4 		– Sell
-26,918
Closed -$2.29M – 550
2017
Q3 		$2.29M Buy
+26,918
New +$2.13M 0.05% 262
2016
Q3 		– Sell
-71,723
Closed -$5.34M – 289
2016
Q2 		$5.34M Buy
+71,723
New +$5.32M 0.15% 134

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voloridge Investment Management's LGND Position: Q2 2026 in Review

Voloridge Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 12,543 shares — an estimated $2.5M sold.

Voloridge Investment Management first reported a position in LGND in Q2 2016 and held it in 23 quarters. The position peaked at $12.7M in Q1 2021. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Voloridge Investment Management reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 12,543 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.5M.
  • Voloridge Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 23 quarters.
  • Voloridge Investment Management's Ligand Pharmaceuticals position peaked at $12.7M in Q1 2021.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.